The companies are working together again on MenaQ7 vitamin K2, after a four-year break.
After a four-year break, vitamin K2 ingredient supplier NattoPharma (Oslo, Norway) and ingredients distributor P.L. Thomas (Morristown, NJ) are once again partnering to promote NattoPharma’s vitamin K2 ingredients for dietary supplements, food and beverage, and nutricosmetics.
The companies originally began working together in 2006 to introduce NattoPharma’s MenaQ7 brand of natural vitamin K2 to the market. Since then, in part due to the companies’ work, awareness of vitamin K2 has increased in the natural products industry. Now, in joining together again, the companies will promote NattoPharma’s MenaQ7 Crystals, introduced last year, which are designed for cost-efficient formulating directly into food and dietary supplement products, without requiring the use of excipients.
P.L. Thomas president Paul Flowerman praised the additional clinical work NattoPharma has done on the MenaQ7 brand, including a recently published 244-patient trial showing health benefits for both heart and bone health.
“In the past year, not only have we received intellectual property recognition in Europe and in the United States, but also, our groundbreaking, three-year clinical study with MenaQ7 for both health has been published in the prestigious journal Osteoporosis International. In tandem, our study showed significant benefits for arterial health,” says NattoPharma CEO Hogne Vik, MD, PhD.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.